SCHEMBL7704945

SCHEMBL7704945

CC1Oc2ccc(CN(Cc3ccccc3)C(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
NCOR2 Q9Y618 1/20 0.44
PARP1 P09874 2/20 0.43
HSD17B10 Q99714 3/20 0.40
ALOX15 P16050 2/20 0.40
ALDH1A1 P00352 3/20 0.38
MAPK1 P28482 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
CTSS P25774 1/20 0.35
BACE1 P56817 2/20 0.35
ABCB1 P08183 1/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PTGES O14684 1/20 0.34
RECQL P46063 1/20 0.34
AKT1 P31749 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6309617 0.98 HDAC1 (0.43) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7704907 0.92 HSD17B10 (0.38) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7704932 0.91 HDAC3 (0.35) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7708255 0.91 RIPK1 (0.36) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7712797 0.91 RIPK1 (0.36) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7708363 0.90 TP53 (0.35) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7711422 0.90 HSD17B10 (0.36) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL6310115 0.90 PARP1 (0.37) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7711073 0.90 MEN1 (0.37) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7704942 0.90 ALDH1A1 (0.37) HDAC3HDAC1HDAC2NCOR2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed